BioCentury | Mar 3, 2021
Product Development

NIH halts COVID-19 convalescent plasma trial, renewing calls for FDA to withdraw authorization

...spokesperson said that “questions related to the specific scenario leading to the decision of the National Institutes of Health...
...unless sound studies are also done efficiently and rapidly.” Steve Usdin U.S. Food and Drug Administration (FDA) Georgetown University In-Q-Tel National Institutes of Health covid-19 cov19pol cov19count convalescent...
BioCentury | Jan 30, 2021
Distillery Therapeutics

CRISPR base editing to treat progeria

...status unavailablePUBLICATION DETAILS: Koblan, L. et al. Nature; published online Jan. 6, 2021doi:10.1038/s41586-020-03086-7CONTACT: Francis S. Collins, National Institutes of Health...
...David R. Liu, Broad Institute of MIT and Harvard, Cambridge, Mass.email: drliu@fas.harvard.edu Claire Quang Broad Institute of MIT and Harvard National Institutes of Health Vanderbilt...
BioCentury | Dec 12, 2020
Translation in Brief

Fecal transplant improves checkpoint inhibitor response in Phase I; plus Secarna’s antitumor antisense oligos, a blood-based mRNA test for Alzheimer’s and more

...ligand 1 PGE2 – Prostaglandin E2 Danielle Golovin Secarna Pharmaceuticals GmbH Princeton University Firebrand Therapeutics Inc. Stanford University Tel Aviv University Molecular Stethoscope Inc. National Institutes of Health Metadherin...
BioCentury | Oct 23, 2020
Regulation

Gilead’s Veklury becomes first FDA approved COVID-19 therapy, with NIH adaptive trial as focal point

...effect did not reach statistical significance for the 10-day course. Karen Tkach Tuzman Veklury, remdesivir (GS-5734) Gilead Sciences Inc. National Institutes of Health U.S...
BioCentury | Oct 14, 2020
Product Development

A third leading COVID program enters holding pattern as NIH pauses testing of Lilly’s mAb

...LY-CoV555 (LY3819253) Skyrizi, risankizumab (ABBV-066, BI 655066) lenzilumab (KB003) Moderna Inc. National Institutes of Health Eli...
BioCentury | Oct 1, 2020
Product Development

Sept. 30 Quick Takes: $234M for NIH’s RADx-UP; plus CureVac, Allena, Covaxx

...By BC Staff NIH in push to improve COVID-19 testing for underserved populationsThe National Institutes of Health has awarded...
BioCentury | Sep 2, 2020
Regulation

NIH: ‘Plasma should not be considered standard of care’

...2020 Elizabeth S. Eaton U.S. Food and Drug Administration (FDA) NIH National Institutes of Health convalescent...
BioCentury | Aug 20, 2020
Politics, Policy & Law

Recommendations to block fetal tissue funding break precedent by going over NIH’s head

...“Industry Must Speak Out Against Fetal Tissue Ban”). Karen Tkach Tuzman U.S. Department of Health and Human Services National Institutes of Health fetal...
BioCentury | Aug 1, 2020
Tools & Techniques

Lurie winner and incoming Genentech R&D chief Aviv Regev looks to gene programs to untangle complex diseases

...such as methods to study cells in living organisms, including humans. The Foundation for the National Institutes of Health...
BioCentury | Jul 25, 2020
Product Development

NIH, HHS fast-tracking point-of-care, pooled tech as way out of testing crunch

...see “Accelerating the Fight against COVID-19 with Real-World Data on Tests” ). Karen Tkach Tuzman, Associate Editor National Institutes of Health U.S...
Items per page:
1 - 10 of 1533
BioCentury | Mar 3, 2021
Product Development

NIH halts COVID-19 convalescent plasma trial, renewing calls for FDA to withdraw authorization

...spokesperson said that “questions related to the specific scenario leading to the decision of the National Institutes of Health...
...unless sound studies are also done efficiently and rapidly.” Steve Usdin U.S. Food and Drug Administration (FDA) Georgetown University In-Q-Tel National Institutes of Health covid-19 cov19pol cov19count convalescent...
BioCentury | Jan 30, 2021
Distillery Therapeutics

CRISPR base editing to treat progeria

...status unavailablePUBLICATION DETAILS: Koblan, L. et al. Nature; published online Jan. 6, 2021doi:10.1038/s41586-020-03086-7CONTACT: Francis S. Collins, National Institutes of Health...
...David R. Liu, Broad Institute of MIT and Harvard, Cambridge, Mass.email: drliu@fas.harvard.edu Claire Quang Broad Institute of MIT and Harvard National Institutes of Health Vanderbilt...
BioCentury | Dec 12, 2020
Translation in Brief

Fecal transplant improves checkpoint inhibitor response in Phase I; plus Secarna’s antitumor antisense oligos, a blood-based mRNA test for Alzheimer’s and more

...ligand 1 PGE2 – Prostaglandin E2 Danielle Golovin Secarna Pharmaceuticals GmbH Princeton University Firebrand Therapeutics Inc. Stanford University Tel Aviv University Molecular Stethoscope Inc. National Institutes of Health Metadherin...
BioCentury | Oct 23, 2020
Regulation

Gilead’s Veklury becomes first FDA approved COVID-19 therapy, with NIH adaptive trial as focal point

...effect did not reach statistical significance for the 10-day course. Karen Tkach Tuzman Veklury, remdesivir (GS-5734) Gilead Sciences Inc. National Institutes of Health U.S...
BioCentury | Oct 14, 2020
Product Development

A third leading COVID program enters holding pattern as NIH pauses testing of Lilly’s mAb

...LY-CoV555 (LY3819253) Skyrizi, risankizumab (ABBV-066, BI 655066) lenzilumab (KB003) Moderna Inc. National Institutes of Health Eli...
BioCentury | Oct 1, 2020
Product Development

Sept. 30 Quick Takes: $234M for NIH’s RADx-UP; plus CureVac, Allena, Covaxx

...By BC Staff NIH in push to improve COVID-19 testing for underserved populationsThe National Institutes of Health has awarded...
BioCentury | Sep 2, 2020
Regulation

NIH: ‘Plasma should not be considered standard of care’

...2020 Elizabeth S. Eaton U.S. Food and Drug Administration (FDA) NIH National Institutes of Health convalescent...
BioCentury | Aug 20, 2020
Politics, Policy & Law

Recommendations to block fetal tissue funding break precedent by going over NIH’s head

...“Industry Must Speak Out Against Fetal Tissue Ban”). Karen Tkach Tuzman U.S. Department of Health and Human Services National Institutes of Health fetal...
BioCentury | Aug 1, 2020
Tools & Techniques

Lurie winner and incoming Genentech R&D chief Aviv Regev looks to gene programs to untangle complex diseases

...such as methods to study cells in living organisms, including humans. The Foundation for the National Institutes of Health...
BioCentury | Jul 25, 2020
Product Development

NIH, HHS fast-tracking point-of-care, pooled tech as way out of testing crunch

...see “Accelerating the Fight against COVID-19 with Real-World Data on Tests” ). Karen Tkach Tuzman, Associate Editor National Institutes of Health U.S...
Items per page:
1 - 10 of 1533